Genetic variation in thrombin-activatable fibrinolysis inhibitor is associated with the risk of diabetic nephropathy.
Journal of endocrinological investigation 2012 Jul 35 (7): 7.
Xu CW, Wu XB, Ma XL, Wang YS, Zhang BC, Zhao JJ, Wang ZJ, Chen J
- Page last reviewed:Jul 30, 2019
- Page last updated:Aug 15, 2019
- Content source: